vs
Side-by-side financial comparison of Claritev Corp (CTEV) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -32.7%, a 34.3% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs 5.0%). Over the past eight quarters, Claritev Corp's revenue compounded faster (2.5% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CTEV vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $177.4M |
| Net Profit | $-80.6M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | 3.9% |
| Net Margin | -32.7% | 1.6% |
| Revenue YoY | 6.2% | 5.0% |
| Net Profit YoY | 41.6% | — |
| EPS (diluted) | $-4.88 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $246.6M | $196.9M | ||
| Q3 25 | $246.0M | $179.5M | ||
| Q2 25 | $241.6M | $181.1M | ||
| Q1 25 | $231.3M | $168.9M | ||
| Q4 24 | $232.1M | $187.3M | ||
| Q3 24 | $230.5M | $168.6M | ||
| Q2 24 | $233.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-80.6M | — | ||
| Q3 25 | $-69.8M | $5.4M | ||
| Q2 25 | $-62.6M | $-4.8M | ||
| Q1 25 | $-71.3M | $4.8M | ||
| Q4 24 | $-138.0M | — | ||
| Q3 24 | $-391.4M | $-143.5M | ||
| Q2 24 | $-576.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -3.1% | 1.2% | ||
| Q3 25 | 4.1% | 3.5% | ||
| Q2 25 | 6.9% | 4.7% | ||
| Q1 25 | 4.2% | 1.2% | ||
| Q4 24 | -17.8% | 13.2% | ||
| Q3 24 | -146.7% | -82.8% | ||
| Q2 24 | -224.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -32.7% | — | ||
| Q3 25 | -28.4% | 3.0% | ||
| Q2 25 | -25.9% | -2.7% | ||
| Q1 25 | -30.8% | 2.8% | ||
| Q4 24 | -59.4% | — | ||
| Q3 24 | -169.8% | -85.1% | ||
| Q2 24 | -247.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-4.88 | $0.05 | ||
| Q3 25 | $-4.23 | $0.12 | ||
| Q2 25 | $-3.81 | $-0.11 | ||
| Q1 25 | $-4.38 | $0.10 | ||
| Q4 24 | $-8.49 | $0.38 | ||
| Q3 24 | $-24.25 | $-3.11 | ||
| Q2 24 | $-35.78 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $144.3M |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $-173.9M | $653.9M |
| Total Assets | $4.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $16.8M | $238.4M | ||
| Q3 25 | $39.2M | $246.3M | ||
| Q2 25 | $56.4M | $445.9M | ||
| Q1 25 | $23.1M | $493.6M | ||
| Q4 24 | $16.8M | $484.6M | ||
| Q3 24 | $86.6M | $453.8M | ||
| Q2 24 | $48.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $4.6B | $372.2M | ||
| Q3 25 | $4.5B | $376.7M | ||
| Q2 25 | $4.5B | $580.5M | ||
| Q1 25 | $4.5B | $583.4M | ||
| Q4 24 | $4.5B | $585.3M | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-173.9M | $693.1M | ||
| Q3 25 | $-101.8M | $727.2M | ||
| Q2 25 | $-39.9M | $757.8M | ||
| Q1 25 | $14.8M | $798.5M | ||
| Q4 24 | $84.0M | $778.3M | ||
| Q3 24 | $207.6M | $749.6M | ||
| Q2 24 | $603.4M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.9B | $1.3B | ||
| Q3 25 | $5.0B | $1.3B | ||
| Q2 25 | $5.1B | $1.5B | ||
| Q1 25 | $5.1B | $1.6B | ||
| Q4 24 | $5.2B | $1.6B | ||
| Q3 24 | $5.3B | $1.5B | ||
| Q2 24 | $5.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | 304.87× | 0.73× | ||
| Q4 24 | 53.67× | 0.75× | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | — |
| Free Cash FlowOCF − Capex | $36.4M | — |
| FCF MarginFCF / Revenue | 14.8% | — |
| Capex IntensityCapex / Revenue | 12.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $66.3M | $43.7M | ||
| Q3 25 | $19.9M | $60.8M | ||
| Q2 25 | $61.2M | $12.0M | ||
| Q1 25 | $-30.1M | $35.5M | ||
| Q4 24 | $-33.4M | $33.1M | ||
| Q3 24 | $72.8M | $53.9M | ||
| Q2 24 | $18.5M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $36.4M | $43.5M | ||
| Q3 25 | $-16.3M | $57.0M | ||
| Q2 25 | $36.6M | $9.3M | ||
| Q1 25 | $-68.9M | $26.9M | ||
| Q4 24 | $-63.8M | $31.0M | ||
| Q3 24 | $41.1M | $49.8M | ||
| Q2 24 | $-7.0M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 14.8% | 22.1% | ||
| Q3 25 | -6.6% | 31.7% | ||
| Q2 25 | 15.2% | 5.1% | ||
| Q1 25 | -29.8% | 15.9% | ||
| Q4 24 | -27.5% | 16.6% | ||
| Q3 24 | 17.8% | 29.6% | ||
| Q2 24 | -3.0% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 12.1% | 0.1% | ||
| Q3 25 | 14.7% | 2.2% | ||
| Q2 25 | 10.2% | 1.5% | ||
| Q1 25 | 16.8% | 5.1% | ||
| Q4 24 | 13.1% | 1.1% | ||
| Q3 24 | 13.8% | 2.4% | ||
| Q2 24 | 10.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
